Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Licenses Use of Kinaxo Proteomics Platform

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies will make its KinaTor chemical proteomics technology available to Takeda San Diego researchers in drug discovery, preclinical research, and clinical development under an agreement announced this week.
Terms of the deal were not disclosed.
The KinaTor platform combines proprietary chemical proteomics technologies with mass spectrometry for the identification and characterization of a drug candidate’s native molecular targets in cell lines and tissue samples.
Takeda San Diego is a wholly owned subsidiary of Takeda Pharmaceutical, based in Osaka, Japan. Kinaxo is a privately held firm based in Martinsreid, Germany.